David T. Rubin to Mesalamine
This is a "connection" page, showing publications David T. Rubin has written about Mesalamine.
Connection Strength
3.826
-
Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol. 2021 01 01; 116(1):125-133.
Score: 0.699
-
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. J Crohns Colitis. 2016 Aug; 10(8):925-33.
Score: 0.499
-
What you see is not always what you get: raising the bar on clinical trial methodology in ulcerative colitis. Gastroenterology. 2013 Jul; 145(1):45-47.
Score: 0.413
-
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011 Mar; 33(6):672-8.
Score: 0.351
-
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis. 2008 Feb; 14(2):265-74.
Score: 0.286
-
5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007 Apr; 13(4):367-71.
Score: 0.270
-
Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol. 2005 Jun; 100(6):1354-6.
Score: 0.237
-
An Insight into Patients' Perspectives of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts. Inflamm Bowel Dis. 2024 Oct 03; 30(10):1748-1758.
Score: 0.227
-
ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019 03; 114(3):384-413.
Score: 0.154
-
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791.
Score: 0.137
-
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis. 2016 08; 22(8):1881-6.
Score: 0.129
-
The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2014 Jul; 24(3):353-65.
Score: 0.110
-
Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May; 39(10):1143-55.
Score: 0.110
-
Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009 Feb 01; 29(3):247-57.
Score: 0.075
-
Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis. Rev Gastroenterol Disord. 2008; 8(1):21-30; quiz 31-2.
Score: 0.071
-
Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. Aliment Pharmacol Ther. 2020 12; 52(11-12):1676-1682.
Score: 0.043
-
Inflammation's role in rectal cancer following prostate radiotherapy, and emerging evidence for a protective role for balsalazide. Gastroenterology. 2005 Aug; 129(2):770-2.
Score: 0.015